CMS issues guidance on IMD treatment option for substance use disorders

The Centers for Medicare & Medicaid Services yesterday released guidance for state Medicaid agencies implementing Section 5052 of the SUPPORT for Patients and Communities Act of 2018, which gives states the option to cover substance use disorder treatment and withdrawal management services for adults who reside primarily in an eligible institution for mental diseases. The guidance provides information on the new state plan option, including requirements related to beneficiary and provider eligibility, clinical screenings, continuum of care, care transitions, and maintenance of existing expenditures.
Related News Articles
Headline
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain…
Headline
The AHA released a new toolkit to improve continuity of care for patients with opioid and stimulant use disorders. Developed with support from the Centers for…
Headline
The Substance Abuse and Mental Health Services Administration July 28 released its latest national survey on drug use and mental health. Among the findings,…
Chairperson's File
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Headline
The Congressional Budget Office today released its estimate of the budgetary effects of the One Big Beautiful Bill Act, as enacted. CBO projects the law will…
Headline
The Centers for Medicare & Medicaid Services July 17 issued two letters to states regarding policies on continuous eligibility and workforce initiatives.…